Earn 1.5 CME Credits
Click below to register.
Friday, January 10, 2020
Fairmont Olympic Hotel
411 University St
Seattle, Washington
Room: Congress
Registration and Breakfast 9:00 AM – 9:30 AM
Interactive CME Activity 9:30 AM – 11:00 AM
Presented by Rush University Medical Center.
This educational activity is supported by independent medical educational grants from Sanofi Genzyme and Shire.
TThe treatment landscape for patients with hemophilia A has changed dramatically over the last several decades. This includes the recent development of extended half-life (EHL) factors and prophylactic treatment protocols that can be administered within the patient’s home, offering those patients the chance to participate in normal activities and achieve average life expectancies. The proposed benefits of EHL factors are numerous, but clinicians must determine when an EHL rFVIII may be the best treatment option. This requires individualized patient management with regard to therapy decision-making, pharmacokinetic variability, and strategies to predict and manage inhibitor development.
Developed by a team of hemophilia experts, these live regional symposia will provide an in-depth assessment of the current state of treating patients with hemophilia A, beginning with a review of the standard and EHL products currently available, consideration of the challenges of prophylaxis dosing, and a review of our current understanding of inhibitor development with FVIII treatment and how to predict, prevent, and treat it. Several case studies will also be discussed to highlight how this clinical information and PK-based dosing can be applied directly to clinical practice, as well as updated information presented the most recent American Society of Hematology Annual Meeting.
The goal of this educational initiative is to provide hematologists, other physicians, and allied healthcare providers (including nurse practitioners and physician assistants), who care for patients with hemophilia A, with the knowledge and skills necessary to make the most appropriate treatment choices for their patients, based on patient preferences, lifestyle, and interpatient variability in pharmacokinetics, and to predict, prevent, and manage inhibitor formation.
This educational initiative is intended to meet the needs of hematologists, other physicians, as well as allied healthcare practitioners (nurse practitioners and physician assistants) who care for patients with hemophilia A. There are no prerequisites.
After participating in this activity, the participant should be able to:
- REVIEW advances in factor-based prophylaxis, including extended half-life factors, for managing hemophilia.
- DESCRIBE the impact of interpatient variability in clotting factor PK profiles on subsequent bleeding risk and related limitations of weight-based dosing.
- EVALUATE recent clinical and technological advances to optimize clotting factor dosing on an individual patient basis.
- ACCESS current and emerging strategies to predict and manage inhibitor development.
- PROPOSE patient-specific prophylactic treatment paradigms for hemophilia A considering the latest evidence-based knowledge.
ACCREDITATION DESIGNATION
In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing
education for the healthcare team.
CREDIT DESIGNATION STATEMENT
Rush University Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
| 9:00 – 9:30 AM |
Registration and Breakfast |
| 9:30 – 9:40 AM |
Conference Goals and Preassessment |
| 9:40 – 10:00 AM |
A Plethora of Choices:
A Look at the Breadth of Standard- and Extended-Half Life Factors
|
| 10:00 – 10:20 AM |
The Challenge of Dosing:
Advances in Individualized Dosing to Improve Bleeding
Outcomes
|
| 10:20 – 10:40 AM |
Addressing Inhibitor Development:
Prediction, Prevention, and Treatment
|
10:40 – 10:55 AM |
Clinical Cases in Hemophilia A: Applying Advances to Practice |
10:55 – 11:00 AM |
Concluding Remarks and Postassessment |
This schedule is subject to change.
Mindy L. Simpson, MD (Chair)
Assistant Professor of Pediatrics
Pediatric Hematology/Oncology
Director, Rush Hemophilia and Thrombophilia Center
Rush University Medical Center
Chicago, Illinois
Lisa N. Boggio, MD
Assistant Professor of Pediatrics
Rush University Medical Center
Rush Hemophilia and Thrombophilia Center
Chicago, Illinois
Jonathan C. Roberts, MD
Associate Medical Director
Bleeding and Clotting Disorders Institute
Assistant Professor of Pediatrics
University of Illinois College at Medicine
Peoria, Illinois
Stacy E. Croteau, MD, MMS
Director Hemophilia/VWD program
Boston Children’s Hospital
Medical Director
Boston Hemophilia Center
Assistant Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts
Michael Wang, MD
Professor of Pediatrics
University of Colorado School of Medicine
Co-Director
University of Colorado Hemophilia and Thrombosis Center
Hematology and CEC Program Leader
Center for Cancer and Blood Disorders
Children’s Hospital Colorado
Aurora, Colorado
Rush University Medical Center and ASiM CE LLC fully comply with the legal requirements of the ADA and the rules and regulations thereof.
There is no fee for this educational activity.
